Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04786392
Other study ID # 2020002809
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date June 2021
Est. completion date June 2021

Study information

Verified date January 2021
Source The University of Queensland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate in healthy adults, 18-40 years of age, how the absorption of 5 mg of L differs between consumption as a supplement, blended foods, and whole food equivalent of blended foods.


Description:

The absorption the macular carotenoids has shown variability between different supplements, and food sources such as egg and spinach. Investigation of the absorption of different forms of food (e.g. cooked, raw, blended) is not as well studied. Investigating the absorption of lutein from different forms of food is important to be able to prescribe lutein from forms of food that will be optimally absorbed.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2021
Est. primary completion date June 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Male and females 18 to 40 years. - Generally healthy. - No participant reported history of clinically significant medical conditions including, but not limited to, cardiovascular, neurological, psychiatric, renal, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled. - Non-smoker. - English language proficiency Exclusion Criteria: - Participant reported diagnosis of serious ocular conditions (e.g. cataracts, glaucoma, diabetic retinopathy, retinitis pigmentosa, Stagardt's disease) - Participant reported diagnosis, or current treatment of age-related macular degeneration. - Participant reported diagnosis of epilepsy. - Participant aversion, intolerance or allergy to study foods to be consumed (spinach, ginger, lemon, apple, flaxseeds) - A female currently pregnant or trying to fall pregnant. - Current or past smoker (within last 12 months). - Under 18 or over 40 years of age. - Currently taking a lutein supplement or consuming large amounts of foods containing lutein on a regular basis (>3 days per week).

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Lutein supplement
5 mg lutein supplement.
Other:
Food, blended
5 mg lutein from baby spinach, blended.
Food, unprocessed
5 mg lutein from baby spinach, in whole food form.

Locations

Country Name City State
Australia School of Human Movement and Nutrition Sciences, The University of Queensland Saint Lucia Queensland

Sponsors (1)

Lead Sponsor Collaborator
The University of Queensland

Country where clinical trial is conducted

Australia, 

References & Publications (12)

Aebischer CP, Schierle J, Schüep W. Simultaneous determination of retinol, tocopherols, carotene, lycopene, and xanthophylls in plasma by means of reversed-phase high-performance liquid chromatography. Methods Enzymol. 1999;299:348-62. — View Citation

Bernstein PS, Li B, Vachali PP, Gorusupudi A, Shyam R, Henriksen BS, Nolan JM. Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Prog Retin Eye Res. 2016 Jan;50:34-66. doi: 10.1016/j.preteyeres.2015.10.003. Epub 2015 Nov 2. Review. — View Citation

Chiu CJ, Chang ML, Zhang FF, Li T, Gensler G, Schleicher M, Taylor A. The relationship of major American dietary patterns to age-related macular degeneration. Am J Ophthalmol. 2014 Jul;158(1):118-127.e1. doi: 10.1016/j.ajo.2014.04.016. Epub 2014 Apr 29. — View Citation

Chung HY, Rasmussen HM, Johnson EJ. Lutein bioavailability is higher from lutein-enriched eggs than from supplements and spinach in men. J Nutr. 2004 Aug;134(8):1887-93. — View Citation

Frede K, Ebert F, Kipp AP, Schwerdtle T, Baldermann S. Lutein Activates the Transcription Factor Nrf2 in Human Retinal Pigment Epithelial Cells. J Agric Food Chem. 2017 Jul 26;65(29):5944-5952. doi: 10.1021/acs.jafc.7b01929. Epub 2017 Jul 13. — View Citation

Howells O, Eperjesi F, Bartlett H. Measuring macular pigment optical density in vivo: a review of techniques. Graefes Arch Clin Exp Ophthalmol. 2011 Mar;249(3):315-47. doi: 10.1007/s00417-010-1577-5. Epub 2011 Jan 8. Review. — View Citation

Kopsell DA, Lefsrud MG, Kopsell DE, Wenzel AJ, Gerweck C, Curran-Celentano J. Spinach cultigen variation for tissue carotenoid concentrations influences human serum carotenoid levels and macular pigment optical density following a 12-week dietary intervention. J Agric Food Chem. 2006 Oct 18;54(21):7998-8005. — View Citation

Liu T, Liu WH, Zhao JS, Meng FZ, Wang H. Lutein protects against ß-amyloid peptide-induced oxidative stress in cerebrovascular endothelial cells through modulation of Nrf-2 and NF-?b. Cell Biol Toxicol. 2017 Feb;33(1):57-67. doi: 10.1007/s10565-016-9360-y. Epub 2016 Nov 22. — View Citation

Taibi G, Nicotra CM. Development and validation of a fast and sensitive chromatographic assay for all-trans-retinol and tocopherols in human serum and plasma using liquid-liquid extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):261-7. — View Citation

van der Made SM, Kelly ER, Kijlstra A, Plat J, Berendschot TT. Increased Macular Pigment Optical Density and Visual Acuity following Consumption of a Buttermilk Drink Containing Lutein-Enriched Egg Yolks: A Randomized, Double-Blind, Placebo-Controlled Trial. J Ophthalmol. 2016;2016:9035745. doi: 10.1155/2016/9035745. Epub 2016 Mar 14. — View Citation

Widomska J, Subczynski WK. Why has Nature Chosen Lutein and Zeaxanthin to Protect the Retina? J Clin Exp Ophthalmol. 2014 Feb 21;5(1):326. — View Citation

Wu J, Seregard S, Algvere PV. Photochemical damage of the retina. Surv Ophthalmol. 2006 Sep-Oct;51(5):461-81. Review. — View Citation

* Note: There are 12 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma lutein concentration Area under the curve of plasma lutein concentrations between 0 and 24 hours post lutein consumption. Study visit 1 (24 hours), Study visit 2 (24 hours), study visit 3 (24 hours)
Secondary Plasma lutein maximum concentration Maximum concentration of plasma lutein reached over 24 hours of measurement, and time point of maximum concentration. Study visit 1 (24 hours), Study visit 2 (24 hours), study visit 3 (24 hours)
Secondary Macular pigment optical density Machine: measured by the Macular Pigment Screener II (Elektron Eye Technology). The non-invasive test uses heterochromatic flicker photometry. One measure completed at each study visit (3 study visits total). Study visit day 1, day 8, day 15
Secondary Daily dietary lutein and zeaxanthin intake Daily dietary intake of lutein and zeaxanthin (mg/day) as measured by a food frequency questionnaire. Study visit day 1
Secondary Daily dietary lutein and zeaxanthin intake Daily dietary intake of lutein and zeaxanthin (mg/day) as measured by a food frequency questionnaire. Study visit day 1, day 8, day 15